

Express Mail No.: EV 335 857 018 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bhagwat et al.

Serial No.: To be Assigned (Continuation of
Application No.: 09/910,950, filed July 23,
2001)

Group Art Unit: To be Assigned

Filed: September 26, 2003

Examiner: To be Assigned

For: INDAZOLE DERIVATIVES AS JNK
INHIBITORS AND COMPOSITIONS
AND METHODS RELATED
THERE TO

Attorney Docket No.: 10624-133-999

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or might be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **AA-BS**, which are listed on the accompanying Form PTO-1449 entitled "List of References Cited By Applicant."

The above-identified application is a continuation of U.S. Application No. 09/910,950, filed July 23, 2001. References **AA-AC** and **AF-BS** are of record in U.S. Application No. 09/910,950. Therefore, pursuant to 37 C.F.R. §1.98(d), Applicants are not required to submit a copy of these references. However, a copy of these references will be made available to the Examiner upon request. A copy of references **AD** and **AE** is enclosed herewith.

Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review references **AA-BS** identified on the attached Form PTO-1449 and make them of record in the file history of the above-identified application by initializing the attached Form PTO-1449.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this Information Disclosure Statement is being submitted before the mailing of a first Office action on the merits, no fee is believed to be due. However, should the Patent and Trademark Office determine that a fee is required, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A duplicate of this document is enclosed for accounting purposes.

Date September 26, 2003

Respectfully submitted,

Anthony M. Insogna, N.Y. No. 35,203
Eg: Matthew E. Long, N.Y. No. 36,343
35,203

Anthony M. Insogna

(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)					ATTY. DOCKET NO. 10624-133-999		APPLICATION NO. To be assigned	
					APPLICANT Bhagwat et al.			
					FILING DATE September 26, 2003		Group 1626	
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA	3,994,890	11/30/76	Fujimura				
	AB	4,415,569	11/15/83	Yasuo et al.				
	AC	6,162,613	12/19/00	Su et al.				
	AD	6,555,539	4/29/03	Reich et al.				
	AE	US 2002/0161022	10/31/02	Reich et al.				
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	AF	WO 99/53927	10/29/99	PCT			YES	NO
	AG	WO 02/085396	10/31/02	PCT				
	AH	WO 01/12621 A1	2/22/01	PCT				
	AI	WO 98/43969	10/8/98	PCT				
	AJ	GB 1293557	09/04/70	Great Britain				
	AK	GB 2 345 486A	7/12/00	Great Britain				
	AL	EP 0 494 774		Europe				
	AM	EP 0 518 805	12/16/92	Europe				
	AN	DE 12 66 763 B	4/25/68	Germany				
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
	AO	Aspenström et al., 1996, "Two GTPases, Cdc42 and Rac, bind directly to a protein implicated in the immunodeficiency disorder Wiskott-Aldrich syndrome", Curr. Biol. <u>6</u> :70-75						
	AP	Chen et al., 1996, "Activation and inhibition of the AP-1 complex in human breast cancer cells", Mol. Carcinogenesis <u>15</u> :215-226						
	AQ	Dong et al., 1998, "Defective T cell differentiation in the absence of <i>Jnk1</i> ", Science <u>282</u> :2092-2095						
	AR	Faris et al., 1996, "Regulation of interleukin-2 transcription by inducible stable expression of dominant negative and dominant active mitogen-activated protein kinase kinase kinase in Jurkat T cells", J. Biol. Chem. <u>271</u> :27366-27373						
	AS	Gum et al., 1997, "Regulation of 92 kDa type IV collagenase expression by the <i>jun</i> aminoterminal kinase- and the extracellular signal-regulated kinase- dependent signaling cascades", Oncogene <u>14</u> :1481-1493						
	AT	Han et al., 1999, "Jun N-terminal kinase in rheumatoid arthritis", J. Pharmacol. Exp. Therap. <u>291</u> :124-130						
	AU	Hibi et al., 1993, "Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain", Genes Dev. <u>7</u> :2135-2148						
	AV	Ishizuka et al., 1997, "Mast cell tumor necrosis factor α production is regulated by MEK kinases", Proc. Natl. Acad. Sci. USA <u>94</u> :6358-6363						
	AW	Karin et al., 1997, "AP-1 function and regulation", Curr. Opin. Cell. Biol. <u>9</u> :240-246						
	AX	Lange-Carter et al., 1993, "A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf", Science <u>260</u> :315-319						
	AY	Li et al., 1996, "Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4 ⁺ T cells", Science <u>271</u> :1272-1276						
	AZ	Li et al., 1996, "The Ras-JNK pathway is involved in shear-induced gene expression", Mol. Cell. Biol. <u>16</u> :5947-5954						

BA	Lin et al., 1995, "Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2", <i>Science</i> <u>268</u> :286-290		
BB	Manning and Mercurio, 1997, "Transcription inhibitors in inflammation", <i>Exp. Opin. Invest. Drugs</i> <u>6</u> :555-567		
BC	Milne et al., 1995, "p53 is phosphorylated <i>in vitro</i> and <i>in vivo</i> by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1", <i>J. Biol. Chem.</i> <u>270</u> :5511-5518		
BD	Mohit et al., 1995, "p49 ^{3F12} kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system", <i>Neuron</i> <u>14</u> :67-78		
BE	Nishina et al., 1997, "Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes", <i>J. Exp. Med.</i> <u>186</u> :941-953		
BF	Okamoto et al., 1997, "Selective activation of the JNK/AP-1 pathway in Fas-mediated apoptosis of rheumatoid arthritis synoviocytes", <i>Arthritis & Rheumatism</i> <u>40</u> :919-926		
BG	Pombo et al., 1994, "The stress-activated protein kinases are major c-Jun amino-terminal kinases activated by ischemia and reperfusion", <i>J. Biol. Chem.</i> <u>269</u> :26546-26551		
BH	Raitano et al., 1995, "The <i>Bcr-Abl</i> leukemia oncogene activates Jun kinase and requires Jun for transformation", <i>Proc.Natl. Acad. Sci. USA</i> <u>92</u> :11746-11750		
BI	Sabapathy et al., 1999, "JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development", <i>Curr. Biol.</i> <u>9</u> :116-125		
BJ	Su et al., 1994, "JNK is involved in signal integration during costimulation of T lymphocytes", <i>Cell</i> <u>77</u> :727-736		
BK	Swantek et al., 1997, "Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF- α) translation: glucocorticoids inhibit TNF- α translation by blocking JNK/SAPK", <i>Mol. Cell. Biol.</i> <u>17</u> :6274-6282		
BL	Szabo et al., 1996, "Altered cJUN expression: an early event in human lung carcinogenesis", <i>Cancer Res.</i> <u>56</u> :305-315		
BM	Tournier et al., 1997, "Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH ₂ -terminal kinase", <i>Proc. Natl. Acad. Sci. USA</i> <u>94</u> :7337-7342		
BN	Whitmarsh and Davis, 1996, "Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways", <i>Mol. Med.</i> <u>74</u> :589-607		
BO	Yan et al., 1994, "Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1", <i>Nature</i> <u>372</u> :798-800		
BP	Yang et al., 1998, "Differentiation of CD4 ⁺ T cells to Th1 cells requires MAP kinase JNK2", <i>Immunity</i> <u>9</u> :575-585		
BQ	Yin et al., 1997, "Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney", <i>J. Biol. Chem.</i> <u>272</u> :19943-19950		
BR	Spiegelman et al., "Regulation of Adipocyte Gene Expression in Differentiation and Syndromes of Obesity/Diabetes", <i>J. of Biol. Chem.</i> <u>268</u> :6823-6826 (1993).		
BS	Hirosumi et al., "A central role for JNK in obesity and insulin resistance", <i>Letters to Nature</i> <u>420</u> :333-336 (2002).		
<table border="1" style="width:100%"> <tr> <td style="width:50%">EXAMINER</td> <td style="width:50%">DATE CONSIDERED</td> </tr> </table>		EXAMINER	DATE CONSIDERED
EXAMINER	DATE CONSIDERED		
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			